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Abstract
Relevance: Cardiovascular diseases continue to be the leading cause of premature adult death.
Lipid profile and atherogenesis: Dislipidaemia leads to subsequent lipid accumulation and migration of immuno-
competent cells into the vessel intima. Macrophages accumulate cholesterol forming foam cells – the morphological 
substrate of atherosclerosis in its initial stage.
Inflammation and atherogenesis: Pro-inflammatory factors provoke oxidative stress, vascular wall damage and foam 
cells formation.
Endothelial and mitochondrial dysfunction in the development of atherosclerosis: Endothelial mitochondria are 
some of the organelles most sensitive to oxidative stress. Damaged mitochondria produce excess superoxide and H2O2, 
which are the main factors of intracellular damage, further increasing endothelial dysfunction.




dymic receptor and reproduces its cytoprotective properties. This indicates the promising use of short-chain derivatives 
of erythropoietin for the treatment and prevention of atherosclerotic vascular injury. In the future, it is planned to study 
the PHBSP derivatives,  the modification of which consists  in adding RGD and PGP  tripeptides with antiaggregant 
properties to the original 11-member peptide.
Copyright Author A et al. This is an open access article distributed under the terms of  the Creative Commons Attribution License (CC-BY 4.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Relevance
The high contribution of cardiovascular pathology to the 
overall structure of the causes of death and disablement in 
developed countries calls for in-depth study and improve-
ment of correction methods. At the same time, the main 
task of research in this area is to find ways to prevent and 








lesions, leading to such nosologies as coronary heart dis-
ease (CHD) and ischemic stroke (Herrington et al. 2016).
Since the middle of the 20th century, most high-income 
countries have experienced a sharp decline in mortality 
due to CHD and brain stroke. For example, in the United 
Kingdom, cardiovascular mortality rates for middle-aged 
men (35-69 years old) fell from around 700 per 100,000 
per year in 1950 to <200 by 2010, and for middle-aged 
women from ≈450 in 1950 to <100 by 2010. Most low- 
and middle-income countries have also reported a decline 
in stroke-related deaths over the past few decades. How-
ever, trends in CHD mortality in these regions have been 
less consistent: some countries have reported a decline, 
while others have reported an increase (especially in some 
Eastern European and Asian countries) in CHD mortality 
(Bennett et al. 2014; Moran et al. 2014).
The Global Burden of Disease 2010 Study showed that 
overal, global age-standardized death rates for both CHD 
and  stroke  decreased  between  1990  and  2010,  with  a 
much higher rate in developed countries than in develop-
ing countries (GBD 2013 Mortality and Causes of Death 
Collaborators 2015). Nevertheless, despite relatively re-
assuring trends, CHD and ischaemic stroke remain the 
leading  causes  of  premature  adult mortality worldwide, 
indicating the highest importance of research into the un-
derlying atherosclerotic process.
Lipid profile and atherogenesis
The introduction of effective methods for preventing and 
correcting the atherosclerotic process directly depends on 
a multi-level understanding of the pathophysiology of the 
vessel wall lesion. Molecular-biological, instrumental and 
other research methods provide consistent information 
on new aspects of the progression of atherosclerosis and 
its clinical complications. These advances have not only 
deepened the understanding of the details of atherogene-
sis, but have also led to the discovery of many unexpect-
ed facts that have called into question many previously 
dominant concepts, and allowed the development of new 
therapeutic approaches to combat cardiovascular disease 
(Libby et al. 2016).
It  is now known that the initial event in the develop-
ment of atherosclerosis is endothelial damage. Endotheli-
al dysfunction (ED) causes infiltration and accumulation 
of low-density lipoprotein cholesterol (LDL) in the sub-
endothelial space. In the pathological conditions, LDLs 
can interact with ROS to form oxidized LDL (oxLDLs) 
(Ketelhuth and Hansson 2011). Modified lipoprotein par-
ticles increase the expression of cell adhesion molecules 
(VCAM-1, P, and E-selectin) in endothelial cells, result-
ing in the recruitment of white blood cells (mainly mono-
cytes and T-lymphocytes) into the subendothelial space. 
These inflammatory cells migrate into the intima during 
the interaction of protein-chemoattractants, such as of 
monocyte MCP-1, eotaxin, and  interferon-γ. Monocytes 
are differentiated into macrophages, express scavewnger 
receptors CD36, SRA, and LOX-1 and internalize mod-
ified lipoproteins. Due to their appearance, macrophages 
loaded with  lipids are called  foam cells,  and  their pres-
ence in the arterial wall is a sign of an early atherosclerot-
ic lesion. T-lymphocytes and mast cells that migrate to the 
intima, along with the foam cells, secrete a wide profile 
of  cytokines, which  contribute  to  inflammation  and  the 
formation of reactive oxygen species (ROSs). The growth 
factors released by these cells and ROSs stimulate the mi-
gration of smooth muscle cells and collagen deposition, 
which leads to the development of atheromatous plaque 
(Kattoor et al. 2017).
In 1912, at a meeting of the Society of Russian Phy-
sicians in St. Petersburg, a major Russian scientist, N.N. 
Anitschkow, whose  name  is  now used  for  the  prize  for 
the most outstanding research in the field of atherosclero-
sis, together with S.S. Khalatov, presented the first results 
of his revolutionary research to identify the relationship 
between nutritional factors, blood cholesterol levels, and 
atherosclerosis.
The main environmental factors determining blood 
cholesterol concentration are the consumption of saturat-
ed and polyunsaturated fats as well as cholesterol in food 
(Keys et al. 1957; Hegsted et al. 1993; Clarke et al. 1997), 
although metabolic, genetic and other factors also influ-
ence cholesterol levels (Dattilo and Kris-Etherton 1992). 
The geographical prevalence of atherosclerosis-associated 
diseases demonstrates their high dependence on national 
diets  around  the world. Atheroprotective  diets  associat-
ed with a lower cardiovascular risk have been identified 
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separately (Mozaffarian et al. 2011). Blood cholesterol (in 
particular, low-density lipoprotein cholesterol) is a widely 
recognised risk factor for CHD, as confirmed by a large 
number of prospective observational studies from around 
the world (Lewington et al. 2007; Baigent et al. 2010).
During the initial phase of atherosclerosis, the pro-
cess  of  fat  infiltration  of  the  vascular wall  (fatty  streak 
stage) is initiated. Macrophages absorb apoB-containing 
lipoproteins,  which  break  down  in  lysosomes,  whereas 
excess free cholesterol enters the endoplasmic reticulum 
and is esterified by a cholesterol enzyme – cholesterol ac-
yltransferase. The resulting cholesterol ether is packaged 
in  cytoplasmic  lipid  droplets,  which  are  characteristic 
of foam cells (Brown et al. 1979; Brown and Goldstein 
1983; Rogacev et al. 2012). The chemical modification of 
ApoB lipoproteins in the form of oxidation and glycation 
enhances their absorption through a number of receptors 
(CD36, acceptor receptor A and a family of lectin-like re-
ceptors) that are not affected by negative feedback from 
excess cholesterol (Moore and Freeman 2006; Younis 
et al. 2008; Polonikov et al. 2017). Enzyme-mediated 
ApoE lipoprotein aggregation increases lipid absorption 
through phagocytosis (Torzewski et al. 2004; Torzewski 
and Lackner 2006), while native lipoprotein residues can 
stimulate the formation of foam cells through the ApoE 
receptor family (LRP1 and VLDLR) (Fujioka et al. 1998; 
Schwartz and Reaven 2012). Native LDL uptake through 
liquid-phase pinocytosis may also stimulate the formation 
of foam cells (Anzinger et al. 2012; Kruth 2013).
In addition to atherogenic lipoproteins, there are also 
atheroprotective  ones,  which  are  responsible  for  trans-
porting  cholesterol  away  from  the  vascular  wall,  thus 
reducing  its  lipid  infiltration.  The  greatest  importance 
was demonstrated for the ApoA-I and HDL proteins that 
transport cholesterol to the liver. In addition to ApoA-I 
and HDLs, ApoE production by macrophages is crucial 
in preventing the formation of atherosclerotic lesions. 
Most ApoE in plasma is produced by the liver, but about 
5-10% is synthesized by macrophages (Linton et al. 
1998). ApoE serves as a ligand for hepatic capture and 
clearance of all the lipoproteins in the ApoB group, ex-
cept LDLs. Knocking out the ApoE gene in mice leads 
to hypercholesterolemia and spontaneous development 
of an atherosclerotic lesion (Zhang et al. 1992; Plump et 
al. 1992).  Therefore, ApoE-deficient  mice  are  some  of 
the most routine models for studying the mechanisms of 
development of atherosclerotic lesions. In studying the 
role of macrophage ApoE in lipoprotein metabolism, its 
crucial  role  in  lipoprotein metabolism between  the vas-
cular  wall  and  blood  was  demonstrated,  making ApoE 
one of the most important targets for atherosclerotic treat-
ment.  Interestingly,  the  atheroprotective  effect  of ApoE 
is implemented through several mechanisms. First, the 
expression of ApoE by hematopoietic stem cells reduc-
es the proliferation and infiltration of monocytes into the 
intima (Murphy et al. 2011). In addition, ApoE reduces 
lysosomal accumulation of cholesterol by increasing li-
pase expression (Wu et al. 2007). It is important that 
ApoE secretion by macrophages stimulates outflow in the 
absence and presence of exogenous acceptors, including 
HDLs and ApoA-I, which do not contain lipids (Mazzone 
and Reardon 1994; Langer et al. 2000; Huang and Maz-
zone 2002). Recent studies have shown that macrophatic 
ApoE facilitates the reverse transport of cholesterol in 
vivo (Zanotti et al. 2011). It also stimulates the outflow of 
phospholipids and cholesterol through ABCA1, ABCG1, 
and SR-BI (Chroni et al 2005; Yancey et al. 2007a; Kim 
et al. 2007; Lammers et al. 2009). In addition to cholester-
ol outflow, macrophage ApoE prevents inflammation (Yu 
et  al.  2004; Ali et al. 2005; Jofre-Monseny et al. 2007; 
Li et al. 2015) and oxidative stress (Miyata and Smith 
1996; Maor et al. 2000; Rosenblat et al. 2002; Rosen-
blat and Aviram 2002). Local ApoE production is likely 
to be a critical atheroprotective mechanism, given that 
the content of atherosclerotic plaques has limited access 
to ApoA-1 and HDLs dissolved in plasma (Fazio et al. 
1997; Fazio et al. 2002). Three common polymorphisms 
of ApoE have been  identified  in  the  human population, 
which  are  of  predictorial  value  in  assessing  the  risk  of 
CHD regardless of plasma cholesterol levels (Davignon 
et al. 1988). ApoE3 is the most common isoform and is 
functionally similar to mouse ApoE. In contrast to iso-
forms ApoE3 and ApoE2, ApoE4 isoform is incapable of 
either stimulating cholesterol outflow (Cullen et al. 1998; 
Gong et al. 2002; Okoro et al. 2012) or preventing inflam-
matory and oxidative activation (Rosenblat and Aviram 
2002; Yu et al. 2004; Huebbe et al. 2010). The dysfunc-
tion  of ApoE4  in  the  host  leads  to  an  increased  risk  of 
CHD compared to people expressing ApoE3 or ApoE2 
(heterozygotes) (Utermann  et  al.  1984; Davignon et al. 
1988; Song et al. 2004).
Thus, the experience gained from N.N. Anichkov’s 
first work demonstrates that in the pathogenesis of athero-
sclerosis, correlated (environmental) factors must be con-
sidered  inextricably  linked  with  genetic  predisposition 
(Zárate et al. 2016). This fact leads to a high proportion of 
research on cardiovascular diseases in the Genome-Wide 
Association Studies (GWAS) programme and the intro-
duction of the found associations in the early genetic di-
agnosis panel. The emergence of GWAS and Mendelian 
randomization analysis opened a new era in the study of 
the pathobiology of atherosclerosis. Modern genetics has 
confirmed the causal role of LDLs in atherogenesis, but 
has also identified new targets that could revolutionize the 
treatment of the atherosclerotic process.
Inflammation and atherogenesis
Activation of pro-inflammatory cascades  in macrophag-
es and endothelium is an essential link in atherogenesis. 
Activated macrophages are prone to an increased gener-
ation of reactive oxygen species, increased cholesterol 
capture and cytokine/chemokine secretion, resulting in 
greater LDL oxidation, endothelial cell activation, mono-
cyte recruitment, and foam cell formation (Brand et al. 
Belyaeva VS et al.: Non-hematopoietic erythropoietin-derived peptides...78
1993; Wang et al. 2002; Bolick et al. 2009; Adamson and 




receptors (Adamson and Leitinger 2011; Chinetti-Gbagu-
idi and Staels 2011; Colin et al. 2014). In addition, plasma 
membrane cholesterol in foam cells increases the trans-
mission of signals through inflammatory receptors (Ye et 





numab,  had  a  significantly  lower  frequency of  repeated 
cardiovascular events, which did not depend on choles-
terol reduction (Ridker et al. 2018).
The formation of macrophage foam cells and transmis-
sion  of  cholesterol-dependent  inflammatory  signals  can 
be reduced by means of removing cholesterol by athero-
protective HDLs and ApoA-Is using a number of mecha-
nisms, including ABCA1-, ABCG1-, and SR-BI-mediat-
ed elimination and water diffusion (Ye et al. 2011; Yancey 
et al. 2007b; Kellner-Weibel and de la Llera-Moya 2011). 
In addition, HDLs and ApoA-Is protect against athero-
sclerosis  by  reducing  inflammation  using  mechanisms 
independent  of  cholesterol  outflow  (Tang et al. 2009; 
Kratzer et al. 2014). In addition, small non-coding RNAs 
have been  found  to  influence  the development of ather-
osclerosis  by  regulating  inflammation  and/or  homeosta-
sis of cholesterol in different types of cells in lesion foci 
(Michell and Vickers 2016; Donaldson et al. 2018). MiR-
33a and MiR-33b contribute to atherosclerosis by dis-
rupting cholesterol outflow and promoting inflammatory 
macrophage conversion (Rayner et al. 2011; Horie et al. 




(Donaldson et al. 2018; Zhuang et al. 2012; Vickers et al. 
2014; Ganta et al. 2017).
Endothelial and mitochondrial 
dysfunction in the development of 
atherosclerosis
Currently, studying the pathobiological processes occur-
ring in endothelial cells in atherosclerosis has led to the 
understanding that one of the most significant factors in 
atherogenesis is mitochondrial dysfunction. Mitochon-
dria are a cell metabolic centre that synthesises the cell’s 
main energy currency, adenosine 5’-triphosphate (ATP), 
through an oxidative phosphorylation reaction. However, 
the role of mitochondria in eukaryotic cells goes beyond 
their ability to act as metabolic mediators. These cellular 
organelles regulate various cellular processes, including 
proliferation (Mitra et al. 2009), an immune response 
(Zhou et al. 2011a), apoptotic cell death (Kroemer et al. 
2007), and also participate in the transmission of intracel-
lular signals to the nucleus (Al-Mehdi et al. 2012). Cells 
in mitochondria vessels are involved in the regulation of 
a wide range of biological processes. Transgenic mice de-
void of a number of mitochondrial proteins usually die 
during  embryogenesis, which  coincides with  the  devel-
opment of the cardiovascular system, or are prone to the 
development of a cardiovascular pathology (Miller et al. 
2010; Shenouda et al. 2011; Dong et al. 2013; Kröller-
Schön et al. 2013).
Direct contact between endothelial cells and the blood-
stream means that they are particularly vulnerable to 
damage from molecules circulating in the blood, on the 
one hand, and that they play an essential “protective” 
role,  on  the  other  hand.  ED  is  associated  with  the  de-
velopment of almost all vascular diseases. Compared to 
cells of other types with higher energy needs, the content 
of mitochondria  in  endotheliocytes  is  relatively  low.  In 
rat endothelials, for example, mitochondria account for 
2-6% of cell volume, whereas in hepatocytes and cardi-
omyocytes – 28% and 32%, respectively (Dromparis and 
Michelakis 2013; Kluge et al. 2013). The low content of 
mitochondria in endothelium indicates that mitochondri-
al-dependent oxidative phosphorylation does not con-
tribute significantly to the energy supply of this tissue. In 
fact, endotheliocytes receive most of their energy from 
anaerobic glycolytic glucose metabolism. For example, 
in cultured endothelial cells, more than 75% of pig aorta 
ATPs is provided by glycolysis (Culic et al. 1997). Sim-
ilar data indicate that mitochondria mainly serve as im-
portant signaling organelles in endothelial and vascular 
vessels (Quintero et al. 2006).
A large number of studies show a causal relationship 
between  mitochondrial  and  endothelial  dysfunctions. 
Phenotypic endotheliocyte dysfunction is highly corre-
lated with mitochondrial biogenesis dysfunction, reduced 
mitochondrial mass and altered expression of electron 
transport chain (ETC) components (Ungvari et al. 2008; 
Dai et al. 2012). Such processes correspond to natural 
processes occurring in endotheliocytes during aging. 
Damaged mitochondria produce excess superoxide and 
H2O2, which are the main determinants of cellular aging 
(Passos et al. 2007).
Mitochondria are an important source of ROSs and at 
the same time have an antioxidant function. Although the 
majority of electrons passing through the redox gradient 
of the ETC eventually reach the V complex, 1-3% of elec-
trons react prematurely with oxygen in complexes I and 
III  to  form superoxide  and other  types of ROSs known 
as mROSs (Quintero et al. 2006). Mitochondrial ROSs 
(mROSs) play a signal role in initiating cellular responses 
to stress. Changing transmembrane potential is an impor-
tant factor that triggers excess mROS production under 
pathological conditions, including hypercholesterolemia, 
hyperglycemia, smoking, infections, and hypoxia. In ad-
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dition to complexes I and III, other sources of mROSs 
have been  identified  in endotheliocytes. One of  them  is 
NADPH oxidase 4 (Nox4) (Lassègue et al. 2012).
Factors that modulate the production of endothelial 
mROSs have been proved to participate in atherosclerosis. 
One of such examples is a protein adapter, p66Shc. The 
fact that the expression of p66Shc may be relevant to the 
cardiovascular function is evident from the observation 
that mice knocked out by p66Shc are protected from ROS-
dependent age-related ED (Francia et al. 2004), ED caused 
by hyperglycemia (Zhou et al. 2011b), and alimentary ath-
erosclerosis (Napoli et al. 2003; Martin-Padura et al. 2008).
Thus, according to the modern understanding of the 
pathogenesis of cardiovascular diseases, mitochondrial 
dysfunction plays a significant role in the development of 
atherosclerosis and related complications (Marzetti et al. 
2013; Chistiakov et al. 2018). Such changes in endotheli-
ocytes and myocytes of the vessel wall lead to structural 
and functional disorders, manifested in the progression of 
atherosclerosis, hypertension and susceptibility to throm-
bosis (Peng et al. 2019). Dysfunction of mitochondria in 
other cells, including neurons and cardiomyocytes, leads 
to  a  decrease  in  their  resistance  to  ischaemia, which  is 
manifested in an increase in lethal outcomes against the 
background of brain stroke, coronary artery occlusion, 
infarction of kidneys and other organs. The emerging 
pathogenetic cascade is becoming a relevant target for a 
pharmacological intervention.
Short erythropoietin-based 
non-hematopoietic peptides as 
innovative atheroprotectors
Based on available information on the pathogenesis of 
atherosclerosis, one approach to treating atherogenesis 
is  to  use  drugs  with  cytoprotective  and  mitochondrial 
activities. The current arsenal of drugs with a mitochon-
drial-oriented mechanism of action includes metabolic 
enchancers (emoxypine and its derivatives, racetames), 
metabolic regulators (trimetazidine, mildronate), and an-
tioxidants (Skulachev ions, SkQ). Preclinical studies in 
vitro and in vivo in recent decades have shown that a 34-




ischemic and traumatic lesions of virtually all organs, 
including endothelium, myocardium, and the brain (Qin 
et al. 2014; Millet et al. 2016; Nekoui and Blaise 2017). 
These properties make it possible to consider EPO as an 
agent with a universal cytoprotective orientation. The re-
mote (hematopoiesis) and paracrine action is associated 
with the ability of EPO to influence the cell cycle and to 
reduce the pro-apoptic orientation of cells, but the eryth-
ropoietic action is mediated by the homodymeric receptor 
complex of the erythropoietin receptor (EPOR/EPOR), 
while the cytoprotective, antioxidant and anti-inflamma-
tory actions are mediated by the heterodymeric complex 
of EPOR/CD131 (Brines et al. 2004).
Despite the promising results of preclinical studies, 
information about the EPO antiapoptic activity received 
by hundreds of research teams is poorly translated into 
clinical reality. As a result, the search for molecules that 
selectively mimic  the  cytoprotective  effects  of EPO  is 
one of the important tasks of modern pharmacology. To 
date,  compounds with  an  amino  acid  sequence  identi-
cal  to  that  of EPO,  but  differing  in  carbohydrate  frag-
ment,  have  become very  common.  Such modifications 
improve the pharmacokinetics and reduce the ability to 
influence hemopoiesis,  preserving  the  tissue-protective 
activity of the molecule. However, these drugs have not 
demonstrated high clinical efficacy as cytoprotectors ei-
ther, possibly due  to  their  low ability  to penetrate his-
togematic barriers. A principally novel approach is the 
search  for  low-molecular  peptide  derivatives  of  EPO, 
which have an antiapoptic activity and freely penetrate 
through biological barriers. The first of such derivatives 
is an 11-amino acid peptide PHBSP, which is an amino 
acid chain ”Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-
Ser-Ser”  and  has  a  selective  affinity  for  the  heterody-
meric complex EPOR/CD131 (Brines  et  al.  2004). In 
developing this peptide, the authors relied on the ami-
no acid sequence of alpha-spiral B erythropoietin, since 
this is the only structural part of the molecule that does 
not participate in the spatial interaction with the homo-
dymeric complex EPOR/EPOR. Several studies have 
shown  that  PHBSP has more pronounced antiapoptic 
properties than the basic molecule, exhibits an analgesic 
activity and does not have a hemopoietic effect intrinsic 
to EPO (Brines et al. 2004; Swartjes et al. 2014; Zhang 
et al. 2017; Yang et al. 2019).  However,  a  significant 
disadvantage of PHBSP is its very short half-life, ap-
proaching several minutes. In addition, studies carried 
out in our laboratory in vivo and in vitro have revealed a 
pro-thrombotic activity in this peptide, which is to some 
extent characteristic of all erythropoietin molecules.
Conclusion
In  our  view,  a  modification  of  PHBSP to improve the 
pharmacokinetic and pharmacodynamic parameters may 
be a further promising development of a short-chain-pep-
tide-based CVD pharmacotherapy. To solve this problem, 
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acid sequence RGD (Arg-Gly-Asp) to PHBSP. It is known 
that this motif has pronounced antiaggregant properties 
(Pytela et al. 1986, Sheu et al. 1995, Hung et al. 2017). 
In parallel, the PGP motive (Pro-Gly-Pro) was added to a 
number of compounds to improve their pharmacokinetic 
characteristics. This amino acid sequence stabilizes the 
molecule in biological media by inhibiting the activity of 
proteolytic enzymes (Shevchenko et al. 2019). Moreover, 
PGP also has the ability to block the angiotensin-conver-
ting enzyme (Wang et al. 2011), one of the most impor-




gregant properties of PGP (Pastorova et al. 2001; Lyapina 
et al. 2007; Liapina et al. 2010), making its adherence to 
PHBSP even more promising. The key question remains 
the nature of embedding RGD and PGP motifs in the base 
molecule. A bioinformatic analysis has made it possible 
to determine the most optimal localizations for joining tri-
peptides, which do not affect the pharmacophores of inte-
rest, preserving both cytoprotective (Korokin et al. 2019; 
Korokin et al. 2020) and antiaggregant activities. Further 
in vitro and in vivo studies will open up the possibility of 
screening the most promising compounds.
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